Mydecine (Mydecine Innovations Group Inc.) is the parent organization of Mindleap, Mydecine Health Sciences, and NeuroPharm.


In July 2020 they have partnered with Leiden University Medical Center (LUMC) to initiate clinical trials for microdosing MDMA/psilocybin formulations. They are also planning to study the use of psilocybin (-assisted therapy) for PTSD in veterans. On which they have also filed a patent (October 2020).

“Leveraging partnerships with scientific, medical, military, and clinical organizations, Mydecine is at the forefront of psychedelic medicine.”

You can find their investor presentation here.

Mydecine raised $13.8 million following the closure of a bought-deal public offering in February 2021. In December 2021, the company raised U$4.4 million through a non-brokered private placement.

The company are raised on the NEO exchange under the ticker MYCO.

Key Staff

  • Joshua Bartch – Director, CEO, Co-Founder
  • Damon Michaels – Director, COO, Co-Founder
  • Rob Roscow – CSO, Co-Founder
  • Jim Gunning – CMO
  • Michael Connolly – CCO
  • Robin Carhart-Harris – Scientific Advisor
  • David Erritzoe – Scientific Advisor


Company Information

Mydecine Website

March, 2020


Explore more company info with a Tree membership

📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates

Explore memberships


HQ / Office Denver, CO, USA
HQ / Office Leiden, Netherlands